Sanwa Kagaku Kenkyusho Co., Ltd.

Kyoichi Asano

Masayasu Kurono

Kiichi Sawai

Yasuaki Kondo

Kenji Miura

Toshinao Usui

Ryoichi Unno

Takuji Yamaguchi

Masato Fukushima

Noriaki Kato

Kuniharu Mizuno

Akira Matsubara

Naofumi Terada

Hiroshi Ozawa

Takahiko Mitani

Yoshiro Ishiwata

Naohisa Ninomiya

Syoji Yokochi

Takuji Kakigami

Yutaka Baba

Hiromoto Kimura

Kazumasa Nakano

Kaneo Yamada

Noriyuki Iwata

Bunkichi Kato

Hiroyuki Ohwaki

Tamaki Ohtuka

Kazumi Niu

Mikio Minamitani

Takashi Meguro

Masashi Taki

Takao Matumoto

Yuichi Shiokawa

Kougaku Isogawa

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Hydantoin derivatives for treating complications of diabetes

The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Glycyrrhetinic acid derivatives

An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.

Composition for enhancing biosynthesis of interferon

A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:

Pharmaceutical composition comprising a medicament and

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivatives, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Process for preparing optically active hydantoins

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

A pharmaceutical composition comprising as an effective ingredient, a pyrazole compound of the formula ##STR1## wherein each of R.sub.1 and R.sub.2 is phenyl or p-halogenophenyl radical, respectively, and R.sub.3 is hydrogen atom or methyl radical, or a salt thereof. The composition is used for curing immunity diseases and a nephropathy.

3-Phenyl-1-phenylpyrazole-4 acetic acid compounds which are useful in

Growing community of inventors

Nagoya, Japan

Kyoichi Asano